Search

Your search keyword '"Salfinger, Max"' showing total 347 results
Start Over Author "Salfinger, Max"
347 results on '"Salfinger, Max"'

1. Updating the approaches to define susceptibility and resistance to anti-tuberculosis agents: implications for diagnosis and treatment

Author

Georghiou, Sophia B, Rodwell, Timothy C, Korobitsyn, Alexei, Abbadi, Said H, Ajbani, Kanchan, Alffenaar, Jan-Willem, Alland, David, Alvarez, Nataly, Andres, Sönke, Ardizzoni, Elisa, Aubry, Alexandra, Baldan, Rossella, Ballif, Marie, Barilar, Ivan, Böttger, Erik C, Chakravorty, Soumitesh, Claxton, Pauline M, Cirillo, Daniela M, Comas, Iñaki, Coulter, Chris, Denkinger, Claudia M, Derendinger, Brigitta, Desmond, Edward P, de Steenwinkel, Jurriaan EM, Dheda, Keertan, Diacon, Andreas H, Dolinger, David L, Dooley, Kelly E, Egger, Matthias, Ehsani, Soudeh, Farhat, Maha R, Fattorini, Lanfranco, Finci, Iris, Le Ray, Laure Fournier, Furió, Victoria, Groenheit, Ramona, Gumbo, Tawanda, Heysell, Scott K, Hillemann, Doris, Hoffmann, Harald, Hsueh, Po-Ren, Hu, Yi, Huang, Hairong, Hussain, Alamdar, Ismail, Farzana, Izumi, Kiyohiko, Jagielski, Tomasz, Johnson, John L, Kambli, Priti, Kaniga, Koné, Karunaratne, GHR Eranga, Sharma, Meenu Kaushal, Keller, Peter M, Kelly, Ellis C, Kholina, Margarita, Kohli, Mikashmi, Kranzer, Katharina, Laurenson, Ian F, Limberis, Jason, Lin, S-Y Grace, Liu, Yongge, López-Gavín, Alexandre, Lyander, Anna, Machado, Diana, Martinez, Elena, Masood, Faisal, Mitarai, Satoshi, Mvelase, Nomonde R, Niemann, Stefan, Nikolayevskyy, Vladyslav, Maurer, Florian P, Merker, Matthias, Miotto, Paolo, Omar, Shaheed V, Otto-Knapp, Ralf, Palaci, Moisés, Gutiérrez, Juan José Palacios, Peacock, Sharon J, Peloquin, Charles A, Perera, Jennifer, Pierre-Audigier, Catherine, Pholwat, Suporn, Posey, James E, Prammananan, Therdsak, Rigouts, Leen, Robledo, Jaime, Rockwood, Neesha, Rodrigues, Camilla, Salfinger, Max, Schechter, Marcos C, Seifert, Marva, Sengstake, Sarah, Shinnick, Thomas, Shubladze, Natalia, Sintchenko, Vitali, Sirgel, Frederick, Somasundaram, Sulochana, Sterling, Timothy R, Spitaleri, Andrea, and Streicher, Elizabeth

Subjects
Medical Microbiology, Biomedical and Clinical Sciences, Clinical Sciences, Infectious Diseases, Biodefense, Antimicrobial Resistance, Prevention, Rare Diseases, Emerging Infectious Diseases, Tuberculosis, Clinical Research, Vaccine Related, Orphan Drug, 5.1 Pharmaceuticals, Development of treatments and therapeutic interventions, Infection, Good Health and Well Being, Antitubercular Agents, Drug Resistance, Bacterial, Drug Resistance, Multiple, Bacterial, Humans, Microbial Sensitivity Tests, Mycobacterium tuberculosis, Tuberculosis, Multidrug-Resistant, Antimycobacterial Susceptibility Testing Group, Medical and Health Sciences, Respiratory System, Cardiovascular medicine and haematology
Abstract

Inappropriately high breakpoints have resulted in systematic false-susceptible AST results to anti-TB drugs. MIC, PK/PD and clinical outcome data should be combined when setting breakpoints to minimise the emergence and spread of antimicrobial resistance. https://bit.ly/3i43wb6

Published
2022

4. Investigating resistance in clinical Mycobacterium tuberculosis complex isolates with genomic and phenotypic antimicrobial susceptibility testing: a multicentre observational study

Author

Finci, Iris, Albertini, Audrey, Merker, Matthias, Andres, Sönke, Bablishvili, Nino, Barilar, Ivan, Cáceres, Tatiana, Crudu, Valeriu, Gotuzzo, Eduardo, Hapeela, Nchimunya, Hoffmann, Harald, Hoogland, Christine, Kohl, Thomas A, Kranzer, Katharina, Mantsoki, Anna, Maurer, Florian P, Nicol, Mark P, Noroc, Ecaterina, Plesnik, Sara, Rodwell, Timothy, Ruhwald, Morten, Savidge, Theresa, Salfinger, Max, Streicher, Elizabeth, Tukvadze, Nestani, Warren, Robin, Zemanay, Widaad, Zurek, Anna, Niemann, Stefan, and Denkinger, Claudia M

Published
2022
Full Text
View/download PDF

5. Population Genomics and Inference of Mycobacterium avium Complex Clusters in Cystic Fibrosis Care Centers, United States

Author

Hasan, Nabeeh A., Davidson, Rebecca M., Epperson, L. Elaine, Kammlade, Sara M., Beagle, Sean, Levin, Adrah R., de Moura, Vinicius Calado, Hunkins, Joshua J., Weakly, Natalia, Sagel, Scott D., Martiniano, Stacey L., Salfinger, Max, Daley, Charles L., Nick, Jerry A., and Strong, Michael

Subjects
Cystic fibrosis -- Complications and side effects, Mycobacterium avium complex -- Identification and classification -- Genetic aspects, Mycobacterial infections -- Risk factors, Disease transmission -- Risk factors, Health
Abstract

Nontuberculous mycobacteria (NTM) are ubiquitous microorganisms found in indoor and outdoor habitats, including water, soil, and dust. NTM can infect susceptible persons, including those with lung diseases such as cystic [...]

Published
2021
Full Text
View/download PDF

8. Culturing Mycobacteria

Author

Wallace, Elizabeth, primary, Hendrickson, Debra, additional, Tolli, Nicholas, additional, Mehaffy, Carolina, additional, Peña, María, additional, Nick, Jerry A., additional, Knabenbaur, Phillip, additional, Watkins, Jackson, additional, Simpson, Anne, additional, Amin, Anita G., additional, Chatterjee, Delphi, additional, Dobos, Karen M., additional, Lahiri, Ramanuj, additional, Adams, Linda, additional, Strong, Michael, additional, Salfinger, Max, additional, Bradford, Rebecca, additional, Stedman, Timothy T., additional, Riojas, Marco A., additional, and Hazbón, Manzour Hernando, additional

Published
2021
Full Text
View/download PDF

12. Mycobacteria: Tuberculosis

Author

Somoskovi, Akos, Salfinger, Max, Mayers, Douglas L., editor, Sobel, Jack D., editor, Ouellette, Marc, editor, Kaye, Keith S., editor, and Marchaim, Dror, editor

Published
2017
Full Text
View/download PDF

13. Genomic Analysis of Cardiac Surgery--Associated Mycobacterium chimaera Infections, United States

Author

Hasan, Nabeeh A., Epperson, L. Elaine, Lawsin, Adrian, Rodger, Rachael R., Perkins, Kiran M., Halpin, Alison Laufer, Perry, K. Allison, Moulton-Meissner, Heather, Diekema, Daniel J., Crist, Matthew B., Perz, Joseph F., Salfinger, Max, Daley, Charles L., and Strong, Michael

Subjects
United States. Centers for Disease Control and Prevention -- Analysis, Surgery -- Analysis -- Health aspects, Genetic research -- Analysis -- Health aspects, Infection -- Analysis -- Health aspects, Cardiac patients -- Analysis -- Health aspects, Genomics -- Analysis -- Health aspects, DNA sequencing, Mycobacterium avium complex, Hospital patients, Genomes, Health
Abstract

Mycobacterium chimaera is a species in the Mycobacterium avium complex (MAC) (1). MAC is the most frequently reported cause of nontuberculous mycobacterium (NTM) infection in the United States, although disseminated [...]

Published
2019
Full Text
View/download PDF

14. Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children

Author

Lewinsohn, David M., Leonard, Michael K., LoBue, Philip A., Cohn, David L., Daley, Charles L., Desmond, Ed, Keane, Joseph, Lewinsohn, Deborah A., Loeffler, Ann M., Mazurek, Gerald H., O'Brien, Richard J., Pai, Madhukar, Richeldi, Luca, Salfinger, Max, Shinnick, Thomas M., Sterling, Timothy R., Warshauer, David M., and Woods, Gail L.

Published
2017

16. Epidemiology of Pulmonary and Extrapulmonary Nontuberculous Mycobacteria Infections in Four U.S. Emerging Infections Program Sites: A Six-Month Pilot

Author

Grigg, Cheri, primary, Jackson, Kelly A, additional, Barter, Devra, additional, Czaja, Christopher A, additional, Johnston, Helen, additional, Lynfield, Ruth, additional, Snippes Vagnone, Paula, additional, Tourdot, Laura, additional, Spina, Nancy, additional, Dumyati, Ghinwa, additional, Cassidy, P Maureen, additional, Pierce, Rebecca, additional, Henkle, Emily, additional, Prevots, D Rebecca, additional, Salfinger, Max, additional, Winthrop, Kevin L, additional, Charles Toney, Nadege, additional, and Magill, Shelley S, additional

Published
2023
Full Text
View/download PDF

19. Epidemiology of Pulmonary and Extrapulmonary Nontuberculous Mycobacteria Infections at 4 US Emerging Infections Program Sites: A 6-Month Pilot.

Author

Grigg, Cheri, Jackson, Kelly A, Barter, Devra, Czaja, Christopher A, Johnston, Helen, Lynfield, Ruth, Vagnone, Paula Snippes, Tourdot, Laura, Spina, Nancy, Dumyati, Ghinwa, Cassidy, P Maureen, Pierce, Rebecca, Henkle, Emily, Prevots, D Rebecca, Salfinger, Max, Winthrop, Kevin L, Toney, Nadege Charles, and Magill, Shelley S

Subjects
MYCOBACTERIAL disease diagnosis, PILOT projects, PUBLIC health surveillance, EXTRAPULMONARY tuberculosis, EVALUATION of human services programs, TIME, MYCOBACTERIUM avium, ACQUISITION of data, TUBERCULOSIS, MEDICAL records, RESEARCH funding, DESCRIPTIVE statistics, MYCOBACTERIAL diseases, DATA analysis software, COLLECTION & preservation of biological specimens, ECONOMIC aspects of diseases
Abstract

Background Nontuberculous mycobacteria (NTM) cause pulmonary (PNTM) and extrapulmonary (ENTM) disease. Infections are difficult to diagnose and treat, and exposures occur in healthcare and community settings. In the United States, NTM epidemiology has been described largely through analyses of microbiology data from health departments, electronic health records, and administrative data. We describe findings from a multisite pilot of active, laboratory- and population-based NTM surveillance. Methods The Centers for Disease Control and Prevention's Emerging Infections Program conducted NTM surveillance at 4 sites (Colorado, 5 counties; Minnesota, 2 counties; New York, 2 counties; and Oregon, 3 counties [PNTM] and statewide [ENTM]) from 1 October 2019 through 31 March 2020. PNTM cases were defined using published microbiologic criteria. ENTM cases required NTM isolation from a nonpulmonary specimen, excluding stool and rectal swabs. Patient data were collected via medical record review. Results Overall, 299 NTM cases were reported (PNTM: 231, 77%); Mycobacterium avium complex was the most common species group. Annualized prevalence was 7.5/100 000 population (PNTM: 6.1/100 000; ENTM: 1.4/100 000). Most patients had signs or symptoms in the 14 days before positive specimen collection (ENTM: 62, 91.2%; PNTM: 201, 87.0%). Of PNTM cases, 145 (62.8%) were female and 168 (72.7%) had underlying chronic lung disease. Among ENTM cases, 29 (42.6%) were female, 21 (30.9%) did not have documented underlying conditions, and 26 (38.2%) had infection at the site of a medical device or procedure. Conclusions Active, population-based NTM surveillance will provide data for monitoring the burden of disease and characterize affected populations to inform interventions. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

20. Herzlichen Glckwunsch

Author

Russi, Erich W., primary, Langloh, Pieter, additional, Karrer, Werner, additional, Puhan, Milo, additional, and Salfinger, Max, additional

Published
2022
Full Text
View/download PDF

21. Joyeux anniversaire

Author

Russi, Erich W., primary, Langloh, Pieter, additional, Karrer, Werner, additional, Puhan, Milo, additional, and Salfinger, Max, additional

Published
2022
Full Text
View/download PDF

24. Updating the approaches to define susceptibility and resistance to anti-tuberculosis agents: implications for diagnosis and treatment

Author

Ministerio de Ciencia e Innovación (España), European Research Council, Comas, Iñaki [0000-0001-5504-9408], Antimycobacterial Susceptibility Testing Group, Georghiou, Sophia B., Rodwell, Timothy C., Korobitsyn, Alexei, Abbadi, Said H., Ajbani, Kanchan, Alffenaar, Jan-Willem, Alland, David, Alvarez, Nataly, Andres, Sönke, Ardizzoni, Elisa, Aubry, Alexandra, Baldan, Rossella, Ballif, Marie, Barilar, Ivan, Böttger, Erik C., Chakravorty, Soumitesh, Claxton, Pauline M., Cirillo, Daniela M., Comas, Iñaki, Coulter, Chris, Denkinger, Claudia M., Derendinger, Brigitta, Desmond, Edward P., Steenwinkel, Jurriaan E. M. de, Dheda, Keertan, Diacon, Andreas H., Dolinger, David L., Dooley, Kelly E., Egger, Matthias, Ehsani, Soudeh, Farhat, Maha R., Fattorini, Lanfranco, Finci, Iris, Fournier Le Ray, Laure, Furió, Victoria, Groenheit, Ramona, Gumbo, Tawanda, Heysell, Scott K., Hillemann, Doris, Hoffmann, Harald, Hsueh, Po-Ren, Hu, Yi, Huang, Hairong, Hussain, Alamdar, Ismail, Farzana, Izumi, Kiyohiko, Jagielski, Tomasz, Johnson, John L., Kambli, Priti, Kaniga, Koné, Karunaratne, G. H. R. Eranga, Sharma, Meenu Kaushal, Keller, Peter M., Kelly, Ellis C., Kholina, Margarita, Kohli, Mikashmi, Kranzer, Katharina, Laurenson, Ian F., Limberis, Jason, Lin, S-Y. Grace, Liu, Yongge, López-Gavín, Alexandre, Lyander, Anna, Machado, Diana, Martínez, Elena, Masood, Faisal, Mitarai, Satoshi, Mvelase, Nomonde R., Niemann, Stefan, Nikolayevskyy, Vladyslav, Maurer, Florian P., Merker, Matthias, Miotto, Paolo, Omar, Shaheed V., Otto-Knapp, Ralf, Palaci, Moisés, Palacios Gutiérrez, Juan José, Peacock, Sharon J., Peloquin, Charles A., Perera, Jennifer, Pierre-Audigier, Catherine, Pholwat, Suporn, Posey, James E., Prammananan, Therdsak, Rigouts, Leen, Robledo, Jaime, Rockwood, Neesha, Rodrigues, Camilla, Salfinger, Max, Schechter, Marcos C., Seifert, Marva, Sengstake, Sarah, Shinnick, Thomas, Shubladze, Natalia, Sintchenko, Vitali, Sirgel, Frederick, Somasundaram, Sulochana, Sterling, Timothy R., Spitaleri, Andrea, Streicher, Elizabeth, Supply, Philip, Svensson, Erik, Tagliani, Elisa, Tahseen, Sabira, Takaki, Akiko, Theron, Grant, Torrea, Gabriela, Van Deun, Armand, van Ingen, Jakko, Van Rie, Annelies, van Soolingen, Dick, Vargas Jr, Roger, Venter, Amour, Veziris, Nicolas, Villellas, Cristina, Viveiros, Miguel, Warren, Robin, Wen, Shu'an, Werngren, Jim, Wilkinson, Robert J., Yang, Caie, Yılmaz, F. Ferda, Zhang, Tingting, Zimenkov, Danila, Ismail, Nazir, Köser, Claudio U., Schön, Thomas, Ministerio de Ciencia e Innovación (España), European Research Council, Comas, Iñaki [0000-0001-5504-9408], Antimycobacterial Susceptibility Testing Group, Georghiou, Sophia B., Rodwell, Timothy C., Korobitsyn, Alexei, Abbadi, Said H., Ajbani, Kanchan, Alffenaar, Jan-Willem, Alland, David, Alvarez, Nataly, Andres, Sönke, Ardizzoni, Elisa, Aubry, Alexandra, Baldan, Rossella, Ballif, Marie, Barilar, Ivan, Böttger, Erik C., Chakravorty, Soumitesh, Claxton, Pauline M., Cirillo, Daniela M., Comas, Iñaki, Coulter, Chris, Denkinger, Claudia M., Derendinger, Brigitta, Desmond, Edward P., Steenwinkel, Jurriaan E. M. de, Dheda, Keertan, Diacon, Andreas H., Dolinger, David L., Dooley, Kelly E., Egger, Matthias, Ehsani, Soudeh, Farhat, Maha R., Fattorini, Lanfranco, Finci, Iris, Fournier Le Ray, Laure, Furió, Victoria, Groenheit, Ramona, Gumbo, Tawanda, Heysell, Scott K., Hillemann, Doris, Hoffmann, Harald, Hsueh, Po-Ren, Hu, Yi, Huang, Hairong, Hussain, Alamdar, Ismail, Farzana, Izumi, Kiyohiko, Jagielski, Tomasz, Johnson, John L., Kambli, Priti, Kaniga, Koné, Karunaratne, G. H. R. Eranga, Sharma, Meenu Kaushal, Keller, Peter M., Kelly, Ellis C., Kholina, Margarita, Kohli, Mikashmi, Kranzer, Katharina, Laurenson, Ian F., Limberis, Jason, Lin, S-Y. Grace, Liu, Yongge, López-Gavín, Alexandre, Lyander, Anna, Machado, Diana, Martínez, Elena, Masood, Faisal, Mitarai, Satoshi, Mvelase, Nomonde R., Niemann, Stefan, Nikolayevskyy, Vladyslav, Maurer, Florian P., Merker, Matthias, Miotto, Paolo, Omar, Shaheed V., Otto-Knapp, Ralf, Palaci, Moisés, Palacios Gutiérrez, Juan José, Peacock, Sharon J., Peloquin, Charles A., Perera, Jennifer, Pierre-Audigier, Catherine, Pholwat, Suporn, Posey, James E., Prammananan, Therdsak, Rigouts, Leen, Robledo, Jaime, Rockwood, Neesha, Rodrigues, Camilla, Salfinger, Max, Schechter, Marcos C., Seifert, Marva, Sengstake, Sarah, Shinnick, Thomas, Shubladze, Natalia, Sintchenko, Vitali, Sirgel, Frederick, Somasundaram, Sulochana, Sterling, Timothy R., Spitaleri, Andrea, Streicher, Elizabeth, Supply, Philip, Svensson, Erik, Tagliani, Elisa, Tahseen, Sabira, Takaki, Akiko, Theron, Grant, Torrea, Gabriela, Van Deun, Armand, van Ingen, Jakko, Van Rie, Annelies, van Soolingen, Dick, Vargas Jr, Roger, Venter, Amour, Veziris, Nicolas, Villellas, Cristina, Viveiros, Miguel, Warren, Robin, Wen, Shu'an, Werngren, Jim, Wilkinson, Robert J., Yang, Caie, Yılmaz, F. Ferda, Zhang, Tingting, Zimenkov, Danila, Ismail, Nazir, Köser, Claudio U., and Schön, Thomas

Abstract

Inappropriately high breakpoints have resulted in systematic false-susceptible AST results to anti-TB drugs. MIC, PK/PD and clinical outcome data should be combined when setting breakpoints to minimise the emergence and spread of antimicrobial resistance.

Published
2022

25. Updating the approaches to define susceptibility and resistance to anti-tuberculosis agents: implications for diagnosis and treatment

Author

Antimycobacterial Susceptibility Testing Group, Georghiou, Sophia B., Rodwell, Timothy C., Korobitsyn, Alexei, Abbadi, Said H., Ajbani, Kanchan, Alffenaar, Jan-Willem, Alland, David, Alvarez, Nataly, Andres, Sönke, Ardizzoni, Elisa, Aubry, Alexandra, Baldan, Rossella, Ballif, Marie, Barilar, Ivan, Böttger, Erik C., Chakravorty, Soumitesh, Claxton, Pauline M., Cirillo, Daniela M., Comas, Iñaki, Coulter, Chris, Denkinger, Claudia M., Derendinger, Brigitta, Desmond, Edward P., Steenwinkel, Jurriaan E. M. de, Dheda, Keertan, Diacon, Andreas H., Dolinger, David L., Dooley, Kelly E., Egger, Matthias, Ehsani, Soudeh, Farhat, Maha R., Fattorini, Lanfranco, Finci, Iris, Fournier Le Ray, Laure, Furió, Victoria, Groenheit, Ramona, Gumbo, Tawanda, Heysell, Scott K., Hillemann, Doris, Hoffmann, Harald, Hsueh, Po-Ren, Hu, Yi, Huang, Hairong, Hussain, Alamdar, Ismail, Farzana, Izumi, Kiyohiko, Jagielski, Tomasz, Johnson, John L., Kambli, Priti, Kaniga, Koné, Karunaratne, G. H. R. Eranga, Sharma, Meenu Kaushal, Keller, Peter M., Kelly, Ellis C., Kholina, Margarita, Kohli, Mikashmi, Kranzer, Katharina, Laurenson, Ian F., Limberis, Jason, Lin, S-Y. Grace, Liu, Yongge, López-Gavín, Alexandre, Lyander, Anna, Machado, Diana, Martínez, Elena, Masood, Faisal, Mitarai, Satoshi, Mvelase, Nomonde R., Niemann, Stefan, Nikolayevskyy, Vladyslav, Maurer, Florian P., Merker, Matthias, Miotto, Paolo, Omar, Shaheed V., Otto-Knapp, Ralf, Palaci, Moisés, Palacios Gutiérrez, Juan José, Peacock, Sharon J., Peloquin, Charles A., Perera, Jennifer, Pierre-Audigier, Catherine, Pholwat, Suporn, Posey, James E., Prammananan, Therdsak, Rigouts, Leen, Robledo, Jaime, Rockwood, Neesha, Rodrigues, Camilla, Salfinger, Max, Schechter, Marcos C., Seifert, Marva, Sengstake, Sarah, Shinnick, Thomas, Shubladze, Natalia, Sintchenko, Vitali, Sirgel, Frederick, Somasundaram, Sulochana, Sterling, Timothy R., Spitaleri, Andrea, Streicher, Elizabeth, Supply, Philip, Svensson, Erik, Tagliani, Elisa, Tahseen, Sabira, Takaki, Akiko, Theron, Grant, Torrea, Gabriela, Van Deun, Armand, van Ingen, Jakko, Van Rie, Annelies, van Soolingen, Dick, Vargas Jr, Roger, Venter, Amour, Veziris, Nicolas, Villellas, Cristina, Viveiros, Miguel, Warren, Robin, Wen, Shu'an, Werngren, Jim, Wilkinson, Robert J., Yang, Caie, Yılmaz, F. Ferda, Zhang, Tingting, Zimenkov, Danila, Ismail, Nazir, Köser, Claudio U., Schön, Thomas, University of Zurich, Antimycobacterial Susceptibility Testing Group, Department of Genetics [Cambridge], University of Cambridge [UK] (CAM), Centre d'Immunologie et des Maladies Infectieuses (CIMI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre Médical de l'Institut Pasteur (CMIP), Institut Pasteur [Paris] (IP)-Université Paris Cité (UPCité), Institut de médecine et d'épidémiologie appliquée [AP-HP Hôpital Bichat-Claude Bernard] (IMEA), AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre d’Infection et d’Immunité de Lille - INSERM U 1019 - UMR 9017 - UMR 8204 (CIIL), Institut Pasteur de Lille, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)-Centre National de la Recherche Scientifique (CNRS), As current or former employees or consultants for FIND, the work of R.B. Baldan, I. Comas, C.M. Denkinger, D.L. Dolinger, S.B. Georghiou, C.U. Köser and T.C. Rodwell on the systematic reviews, including this viewpoint, was supported by Unitaid (grant 2019-32-FIND MDR), BMGF (grant OPP1105925), the German Federal Ministry of Education and Research through KfW, the Dutch Ministry of Foreign Affairs, the Australian Department of Foreign Affairs and Trade, and UK aid from the British people. N. Alvarez and J. Robledo are funded by MinCiencias, Colombia (number 221389666216 CT-783-2018). A. Aubry and N. Veziris work at the Centre National de Reference des Mycobactéries, which receives an annual grant from Santé Publique France and have received research grants from Janssen for studies on bedaquiline. P. Claxton and I.F. Laurenson are funded through National Services Scotland. I. Comas was supported by PID2019-104477RB-I00 from the Spanish Science Ministry and by ERC (CoG 101001038). M. Egger is supported by the Swiss National Science Foundation (grant number 320030_153442 and 189498) and the US National Institutes of Health, National Institute of Allergy and Infectious Diseases, the Eunice Kennedy Shriver National Institute of Child Health and Human Development, the National Cancer Institute, the National Institute of Mental Health, the National Institute on Drug Abuse, the National Heart, Lung, and Blood Institute, the National Institute on Alcohol Abuse and Alcoholism, the National Institute of Diabetes and Digestive and Kidney Diseases, the Fogarty International Center, and the National Library of Medicine: Asia-Pacific, U01AI069907, CCASAnet, U01AI069923, Central Africa, U01AI096299, East Africa, U01AI069911, NA-ACCORD, U01AI069918, Southern Africa, U01AI069924, West Africa, U01AI069919. M.R. Farhat is supported by NIH NIAID R01AI155765. S.K. Heysell was funded by NIH NIAID grants R01 AI137080 and U01 AI150508. T. Jagielski was supported by a DAINA grant (number 2017/27/L/NZ6/03279) from the National Science Centre, Poland. J.L. Johnson was supported by contracts NO1-AI95383 and NO1-AI-70022 of the US National Institutes of Health. P.M. Keller was supported by Innosuisse 36198.1 IP-LS. C.U. Köser is a research associate at Wolfson College and visiting scientist at the Department of Genetics, University of Cambridge. The Federal Government of Germany supported C.U. Köser as part of his work for the European Laboratory Initiative, WHO Regional Office for Europe. C.U. Köser was further supported by the Royal Society of Tropical Medicine and Hygiene and the National Institute for Health Research Cambridge Biomedical Research Centre and received an observership by the European Society of Clinical Microbiology and Infectious Diseases to the EUCAST Development Laboratory for Bacteria (Växjö, Sweden), hosted by Gunnar Kahlmeter and Erika Matuschek. D. Machado and M. Viveiros are funded in part by Fundação para a Ciência e a Tecnologia, Portugal (PTDC/BIA-MIC/30692/2017, UID/Multi/04413/2020 and DL57/ CEECIND/0256/2017). S. Niemann is supported by the German Center for Infection Research, Excellenz Cluster Precision Medicine in Chronic Inflammation EXC 2167, Leibniz Science Campus Evolutionary Medicine of the LUNG (EvoLUNG). S.V. Omar has received funding to prepare and provide training for Janssen Pharmaceutica activities. L. Rigouts is supported by the Belgian Directorate General for Development. T.C. Rodwell was additionally funded in part by FIND and NIH NIAD, grants: P30 AI036214 and R21 AI135756. T. Schön is funded by the Swedish Heart and Lung Foundation and the Swedish Research Council. T.R. Sterling has received funding from the US National Institutes of Health and the Centers for Disease Control and Prevention. G. Theron and R. Warren are supported by baseline funding from the South African Medical Research Council. R.J. Wilkinson receives funding from the Wellcome Trust (203135) and from the Francis Crick Institute, which is supported by Cancer Research UK (FC0010218), UKRI (FC0010218) and the Wellcome Trust (FC0010218), Ministerio de Ciencia e Innovación (España), European Research Council, Comas, Iñaki, Comas, Iñaki [0000-0001-5504-9408], Antimycobacterial Susceptibility T, and Wellcome Trust

Subjects
[SDV]Life Sciences [q-bio], Respiratory System, Drug Resistance, Antitubercular Agents, Infektionsmedicin, Medical and Health Sciences, Drug Resistance, Multiple, Bacterial, Tuberculosis, Multidrug-Resistant, 11 Medical and Health Sciences, Human Biology & Physiology, MESH: Microbial Sensitivity Tests, 10179 Institute of Medical Microbiology, Bacterial, Multidrug-Resistant, Infectious Diseases, 5.1 Pharmaceuticals, Development of treatments and therapeutic interventions, Infection, Life Sciences & Biomedicine, Multiple, Model organisms, Pulmonary and Respiratory Medicine, Infectious Medicine, Immunology, Infectious Disease, 610 Medicine & health, Microbial Sensitivity Tests, Vaccine Related, Rare Diseases, Clinical Research, Biodefense, MESH: Drug Resistance, Bacterial, Drug Resistance, Bacterial, Tuberculosis, Humans, Science & Technology, MESH: Humans, Antimycobacterial Susceptibility Testing Group, FOS: Clinical medicine, Prevention, MESH: Drug Resistance, Multiple, Bacterial, Mycobacterium tuberculosis, Eucast, MESH: Antitubercular Agents, lnfectious Diseases and Global Health Radboud Institute for Health Sciences [Radboudumc 4], Orphan Drug, Emerging Infectious Diseases, Good Health and Well Being, 2740 Pulmonary and Respiratory Medicine, 570 Life sciences, biology, Human medicine, Antimicrobial Resistance, Model
Abstract

11 páginas, 2 figuras, 1 tabla, Inappropriately high breakpoints have resulted in systematic false-susceptible AST results to anti-TB drugs. MIC, PK/PD and clinical outcome data should be combined when setting breakpoints to minimise the emergence and spread of antimicrobial resistance., I. Comas was supported by PID2019-104477RB-I00 from the Spanish Science Ministry and by ERC (CoG 101001038)

Published
2022

26. Benchmarking the empirical accuracy of short-read sequencing across the M. tuberculosis genome

Author

Marin, Maximillian, primary, Vargas, Roger, additional, Harris, Michael, additional, Jeffrey, Brendan, additional, Epperson, L Elaine, additional, Durbin, David, additional, Strong, Michael, additional, Salfinger, Max, additional, Iqbal, Zamin, additional, Akhundova, Irada, additional, Vashakidze, Sergo, additional, Crudu, Valeriu, additional, Rosenthal, Alex, additional, and Farhat, Maha Reda, additional

Published
2022
Full Text
View/download PDF

27. Population Genomics of Mycobacterium abscessus from U.S. Cystic Fibrosis Care Centers

Author

Davidson, Rebecca M., primary, Hasan, Nabeeh A., additional, Epperson, L. Elaine, additional, Benoit, Jeanne B., additional, Kammlade, Sara M., additional, Levin, Adrah R., additional, Calado de Moura, Vinicius, additional, Hunkins, Joshua, additional, Weakly, Natalia, additional, Beagle, Sean, additional, Sagel, Scott D., additional, Martiniano, Stacey L., additional, Salfinger, Max, additional, Daley, Charles L., additional, Nick, Jerry A., additional, and Strong, Michael, additional

Published
2021
Full Text
View/download PDF

28. 1408. Population-based Nontuberculous Mycobacteria Surveillance in Four Emerging Infections Program Sites, October 2019–March 2020

Author

Jackson, Kelly A, primary, Barter, Devra, additional, Czaja, Christopher A, additional, Johnston, Helen, additional, Lynfield, Ruth, additional, Vagnone, Paula Snippes, additional, Tourdot, Laura, additional, Spina, Nancy, additional, Dumyati, Ghinwa, additional, Peters, Shantel, additional, Escutia, Gabriela, additional, Pierce, Rebecca, additional, Henkle, Emily, additional, Prevots, D Rebecca, additional, Salfinger, Max, additional, Winthrop, Kevin L, additional, Toney, Nadege Charles, additional, Magill, Shelley, additional, and Grigg, Cheri, additional

Published
2021
Full Text
View/download PDF

31. The molecular basis of resistance to isoniazid, rifampin, and pyrazinamide in Mycobacterium tuberculosis

Author

Parsons Linda M, Somoskovi Akos, and Salfinger Max

Subjects
drug resistance, isoniazid, Mycobacterium tuberculosis, pyrazinamide, rifampin, Diseases of the respiratory system, RC705-779
Abstract

Abstract Multidrug-resistant (MDR) strains of Mycobacterium tuberculosis have emerged worldwide. In many countries and regions, these resistant strains constitute a serious threat to the efficacy of tuberculosis control programs. An important element in gaining control of this epidemic is developing an understanding of the molecular basis of resistance to the most important antituberculosis drugs: isoniazid, rifampin, and pyrazinamide. On the basis of this information, more exacting laboratory testing, and ultimately more appropriate and timely treatment regimens, can be developed.

Published
2001
Full Text
View/download PDF

33. On the Consequences of Poorly Defined Breakpoints for Rifampin Susceptibility Testing of Mycobacterium tuberculosis Complex

Author

Koser, Claudio U., Georghiou, Sophia B., Schön, Thomas, Salfinger, Max, Koser, Claudio U., Georghiou, Sophia B., Schön, Thomas, and Salfinger, Max

Abstract

In a recent report of a systematic review of critical concentrations (CCs), the World Health Organization (WHO) lowered the rifampin (RIF) CC for antimicrobial susceptibility testing (AST) of the Mycobacterium tuberculosis complex using Middlebrook 7H10 medium and the Bactec Mycobacterial Growth Indicator Tube (MGIT) 960 system from 1 to 0.5mg/ ml. The previous RIF CC for 7H10 had been in use for over half a century. Because it had served as the de facto reference standard, it contributed to the endorsement of inappropriately high CCs for other AST methods, including the U.S. Food and Drug Administration (FDA)-approved MGIT system. Moreover, this resulted in confusion about the interpretation of seven borderline resistance mutations in rpoB (i.e., L430P, D435Y, H445L, H445N, H445S, L452P, and I491F). In this issue of the Journal of Clinical Microbiology, Shea et al. (J Clin Microbiol 59:e01885-20, 2021, https://doi.org/10.1128/JCM.01885-20) provide evidence that the CC endorsed by the Clinical and Laboratory Standards Institute for the Sensititre MYCOTB system, which is not FDA approved but is CE-IVD marked in the European Union, is likely also too high. These findings underscore the importance of calibrating AST methods against a rigorously defined reference standard, as recently proposed by the European Committee on Antimicrobial Susceptibility Testing, as well as the value of routine next-generation sequencing for investigating discordant AST results.

Published
2021
Full Text
View/download PDF

34. Genomic sequence characteristics and the empiric accuracy of short-read sequencing

Author

Marin, Maximillian, primary, Vargas, Roger, additional, Harris, Michael, additional, Jeffrey, Brendan, additional, Epperson, L. Elaine, additional, Durbin, David, additional, Strong, Michael, additional, Salfinger, Max, additional, Iqbal, Zamin, additional, Akhundova, Irada, additional, Vashakidze, Sergo, additional, Crudu, Valeriu, additional, Rosenthal, Alex, additional, and Farhat, Maha Reda, additional

Published
2021
Full Text
View/download PDF

38. Universal genotyping in tuberculosis control program, New York City, 2001-2003

Author

Clark, Carla M., Driver, Cynthia R., Munsiff, Sonal S., Driscoll, Jeffrey R., Kreiswirth, Barry N., Zhao, Benyang, Ebrahimzadeh, Adeleh, Salfinger, Max, Piatek, Amy S., and Abdelwahab, Jalaa'

Subjects
Genotype -- Research, Tuberculosis -- Research, Tuberculosis -- Prevention
Abstract

In 2001, New York City implemented genotyping to its tuberculosis (TB) control activities by using IS6110 restriction fragment length polymorphism (RFLP) and spoligotyping to type isolates from culture-positive TB patients. [...]

Published
2006

43. Population Genomics of from U.S. Cystic Fibrosis Care Centers.

Author

Davidson, Rebecca M., Hasan, Nabeeh A., Epperson, L. Elaine, Benoit, Jeanne B., Kammlade, Sara M., Levin, Adrah R., de Moura, Vinicius Calado, Hunkins, Joshua, Weakly, Natalia, Beagle, Sean, Sagel, Scott D., Martiniano, Stacey L., Salfinger, Max, Daley, Charles L., Nick, Jerry A., Strong, Michael, and Calado de Moura, Vinicius

Subjects
ANTIBIOTICS, RESEARCH, RESEARCH methodology, MEDICAL cooperation, EVALUATION research, CYSTIC fibrosis, COMPARATIVE studies, GENOMICS, GENOMES, RESEARCH funding, MYCOBACTERIAL diseases, MICROBIAL sensitivity tests
Abstract

Rationale:Mycobacterium abscessus is a significant threat to individuals with cystic fibrosis (CF) because of innate drug resistance and potential transmission between patients. Recent studies described global dominant circulating clones of M. abscessus, but detailed genomic surveys have not yet been described for the United States. Objectives: We examined the genetic diversity of respiratory M. abscessus isolates from U.S. patients with CF and evaluated the potential for transmission events within CF Care Centers. Methods: Whole-genome sequencing was performed on 558 M. abscessus isolates from 266 patients with CF attending 48 CF Care Centers in 28 U.S. states as part of a nationwide surveillance program. U.S. isolates were also compared with 64 isolate genomes from 13 previous studies to evaluate the prevalence of recently described dominant circulating clones. Results: More than half of study patients with CF and M. abscessus had isolates within four dominant clones; two clones of M. abscessus subspecies (subsp.) abscessus (MAB) and two clones of M. abscessus subsp. massiliense (MMAS). Acquired drug resistance mutations for aminoglycosides and macrolides were rare in the isolate population, and they were not significantly enriched in dominant clones compared with unclustered isolates. For a subset of 55 patients, there was no relationship between dominant clones and diagnosis of active lung disease (P = 1.0). Twenty-nine clusters of genetically similar MAB isolates and eight clusters of genetically similar MMAS isolates were identified. Overall, 28 of 204 (14%) patients with MAB and 15 of 64 (23%) patients with MMAS had genetically isolates similar to those of at least one other patient at the same CF Care Center. Genetically similar isolates were also found between 60 of 204 (29%) patients with MAB and 19 of 64 (30%) patients with MMAS from different geographic locations. Conclusions: Our study reveals the predominant genotypes of M. abscessus and frequency of shared strains between patients in U.S. CF Care Centers. Integrated epidemiological and environmental studies would help to explain the widespread presence of dominant clones in the United States, including the potential for broad distribution in the environment. Single site studies using systematic, evidence-based approaches will be needed to establish the contributions of health care-associated transmission versus shared environmental exposures. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

44. List of Contributors

Author

Ackers, Marta-Louise, primary, Cohen, Mary Ann Adler, additional, Akfirat, Gokhan L., additional, Alfonso, César A., additional, Allende, Maria C., additional, Arshad, Aysha, additional, Ashkin, David, additional, Bansal, Ajay, additional, Bartholow, Bradford N., additional, Bayer, Ronald, additional, Bertozzi, Stefano, additional, Boone, Lawrence R., additional, Cardo, Denise M., additional, Carlos, Maria P., additional, Carr, Andrew, additional, Chaisson, Richard E., additional, Chiarello, Linda A., additional, Cooper, David A., additional, Cowan, Elliot P., additional, De Girolami, Umberto, additional, DeHovitz, Jack A., additional, DeSimone, Joseph A., additional, Diesing, Scott, additional, Dorak, M. Tevfik, additional, Doweiko, John P., additional, Ferrigno, Lisa, additional, Finley, James L., additional, Fleming, Patricia L., additional, Flexner, Charles, additional, Friedman-Kien, Alvin E., additional, Frishman, William H., additional, Gabuzda, Dana, additional, Gardner, Murray B., additional, Garvey, Edward P., additional, Gelbard, Harris, additional, Gendelman, Howard E., additional, Gholam, Pierre M., additional, Goff, Stephen P., additional, Hale, Yvonne, additional, Hollender, Elena, additional, Holtgrave, David R., additional, Horowitz, Harold W., additional, Hu, Dale J., additional, Jabs, Douglas A., additional, Janssen, Robert S., additional, Johnson, Daniel A., additional, Joshi, Vijay V., additional, Kanki, Phyllis J., additional, Kaslow, Richard A., additional, King, Susan M., additional, Klotman, Mary, additional, Klotman, Paul E., additional, Koppel, Barbara S., additional, Kotler, Donald P., additional, Lane, H. Clifford, additional, Laurence, Jeffrey, additional, Lauzardo, Michael, additional, Leschek, Judith D., additional, Lindegren, Mary Lou, additional, Lowenstein, Arlene J., additional, Luciw, Paul A., additional, Mallon, Patrick W.G., additional, Mastro, Timothy D., additional, Nachman, Sharon, additional, Nakashima, Allyn K., additional, Narita, Masahiro, additional, O'Connor, Paula, additional, Onorato, Ida M., additional, Opuni, Marjorie, additional, Panlilio, Adelisa L., additional, Penzak, Scott R., additional, Perelson, Alan S., additional, Peterson, John L., additional, Pieniazek, Danuta, additional, Piscitelli, Stephen C., additional, Pitchenik, Arthur E., additional, Pomerantz, Roger J., additional, Ribeiro, Ruy M., additional, Richman, Douglas, additional, Rogers, Martha F., additional, Romines, Karen R., additional, Salfinger, Max, additional, Sanchez, Miguel, additional, Sankalé, Jean-Louis, additional, Scadden, David T., additional, Schooley, Robert T., additional, Sedaghat, Ahmad R., additional, Sharer, Leroy R., additional, Siliciano, Robert F., additional, Smith, Davey, additional, Smith, Nancy L., additional, Sotrel, Ana, additional, Sowell, Richard L., additional, Spicer, Troy, additional, Stambaugh, Jerry Jean, additional, Swindells, Susan, additional, Tang, James (Jianming), additional, Wagner, Krystn R., additional, Weiss, Stanley H., additional, Winston, Jonathan A., additional, Wolitski, Richard J., additional, Wong, Joseph K., additional, and Wormser, Gary P., additional

Published
2004
Full Text
View/download PDF

45. Mycobacterial Disease in Patients with HIV Infection

Author

Ashkin, David, primary, Hale, Yvonne, additional, Hollender, Elena, additional, Lauzardo, Michael, additional, Narita, Masahiro, additional, Pitchenik, Arthur E., additional, Salfinger, Max, additional, and Stambaugh, Jerry Jean, additional

Published
2004
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results